期刊文献+

抗脊髓灰质炎病毒Ⅰ型D抗原单克隆抗体的制备及其初步应用 被引量:2

Preparation and preliminary application of monoclonal antibody against D antigen of poliovirus typeⅠ
原文传递
导出
摘要 目的制备脊髓灰质炎病毒(Poliovirus)Ⅰ型D抗原单克隆抗体,并建立双抗体夹心ELISA检测方法。方法采用Vero细胞培养脊髓灰质炎病毒Ⅰ型,柱层析纯化病毒抗原,SDS-PAGE鉴定病毒蛋白,HPLC分析抗原纯度,Western blot分析抗原的反应原性。以纯化的脊髓灰质炎病毒Ⅰ型D抗原免疫BALB/c小鼠,进行细胞融合,筛选可分泌脊髓灰质炎病毒I型D抗原单克隆抗体的杂交瘤细胞株。单克隆抗体经纯化后,采用间接ELISA法检测小鼠腹水抗体效价、单抗的特异性及相对亲和力。分别以纯化的单抗作为捕获抗体和酶标抗体,进行配对试验,建立用于脊髓灰质炎病毒Ⅰ型D抗原检测的双抗体夹心ELISA方法,确定方法的最佳线性范围,并验证方法的特异性。结果纯化的脊髓灰质炎病毒Ⅰ型D抗原经SDS-PAGE分析,共显示4条蛋白条带,相对分子质量分别为约40 000、35 000、32 000和28 000;经HLPC分析,纯度达99%;小鼠免疫血清可与相对分子质量约为35 000的VP1蛋白发生特异性反应。共筛选出5株可稳定分泌脊髓灰质炎病毒I型D抗原单克隆抗体的阳性杂交瘤细胞株,纯化的单抗仅与D抗原发生反应;2H1和3B5株单抗的效价分别为2×107和2×106,且亲和力高于其他3株单抗。采用2H1和3B5株单抗配对,可以特异性检测D抗原,而与C抗原不反应;D抗原最佳线性范围为4.300~0.071 DU/ml,R2为0.994 6。该法仅可检出脊髓灰质炎病毒Ⅰ型D抗原,而与脊髓灰质炎病毒Ⅱ型、Ⅲ型D抗原和脊髓灰质炎病毒Ⅰ型C抗原、EV71抗原、Vero细胞培养上清不发生交叉反应。结论制备了脊髓灰质炎病毒Ⅰ型D抗原单克隆抗体,建立了可用于脊髓灰质炎病毒Ⅰ型D抗原特异性检测的双抗体夹心ELISA方法。 Objective To prepare monoclonal antibody (McAb) against D antigen of poliovirus type I and develop a double antibody sandwich ELISA method. Methods Poliovims type I was cultured in Vero cells, from which viral antigen was purified by column chromatography, and analyzed for viral protein by SDS-PAGE, for purity by HPLC method and for reactogenicity by Western blot. BALB/c mice were immunized with purified D antigen of poliovirus type I , based on which the hybridoma cell strains secreting McAbs were screened by cell fusion. The secreted MeAbs were purified, and determined for titer, specificity and relative affinity by indirect ELISA. Match test was performed using the purified McAbs as capture and detection antibodies respectively, base on which a double antibody sandwich ELISA method for D antigen of poliovirus type I was developed, determined for the optimal linear range and verified for specificity. Results Purified D antigen of poliovirus type I showed four bands on SDS-PAGE profile, with relative molecular masses of about 40 000, 35 000, 32 000 and 28 000 respectively, and reached a purity of 99%. Murine immune sera showed specific reaction with the VP1 protein with a relative molecular mass of about 35 000. A total of five hybridoma cell strains stably secreting McAbs against D antigen of poliovirus type I were screened, and the purified McAbs showed only reaction with D antigen. McAbs 2H1 and 3B5 reached titers of 2 ~ 107 and 2 ~ 106 respectively, of which the affinities were higher than those secreted by the other three hybridoma cell strains, McAb 2H1 matched to McAb 3B5 showed specific reaction with D antigen while no reaction with C antigen. The optimal linear detection range of D antigen by the developed ELISA method was 4. 300 ~ 0. 071 DU/ml, with a R2 value of 0. 994 6. The D antigen of poliovirus type I was detected by the developed method, while no cross reactions with D antigens of poliovirus types ]I andre, the C antigen of poliovirus type | , EVT1 antigen or culture supernatant of Vero cells were observed. Conclusion The McAbs against D antigen of poliovirus type I were prepared, based on which a double antibody sandwich ELISA method suitable for specific detection of the said antigen was developed.
出处 《中国生物制品学杂志》 CAS CSCD 2012年第1期82-86,共5页 Chinese Journal of Biologicals
基金 国药集团新产品基金项目(2011SW06)
关键词 脊髓灰质炎病毒 D抗原 C抗原 抗体 单克隆 酶联免疫吸附测定 Poliovirus D antigen C antigen Antibody monoelonal ELISA
  • 相关文献

参考文献8

  • 1Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin po- liovirus strains [J]. Expert Rev Vaccines, 2011, 10 (5): 635-644.
  • 2Centers for Disease Control and Prevention(CDC). Progress toward global eradication of poliomyelitis, 2002 [J]. MMWR Morb Mortal Wkly Rep, 2003, 52 (16): 366-369.
  • 3Arya SC, Agarwal N. Prospective inactivated or live poliovirus vaccine: effectiveness in the 21st century [J]. Expert Rev Vac- cines, 2009, 8 (2): 127-130.
  • 4Sawyer LA, Mclnnis J, Albrecht P. Quantitation of D antigen con- tent in inactivated poliovirus vaccine derived from wild-type or sabin strains [J]. Biologicals, 1993, 21 (2): 169-177.
  • 5王辉,张月兰,过琴媛,贾丽丽,钟书声,赵玉秀,马可,罗书荣.疫苗制品中Vero细胞残余蛋白含量检测方法的建立[J].中国生物制品学杂志,2007,20(12):937-939. 被引量:19
  • 6Zola H. Monoclonal antibodies [M]. Oxford: Bias Scientific Pub- lisher Limited, 2000: 23-24.
  • 7Sawyer LA, Wood D, Ferguson M, et al. Potency of wild-type or Sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibodies specific for each antigenic site [J]. Biologicals, 1997, 25 (3): 299-306.
  • 8Rezapkin G, Dragunsky E, Chumakov K. Improved ELISA test for determination of potency of inactivated poliovirus vaccine (IPV) [J]. Biologicals, 2005, 33 ( 1 ) : 17-27.

二级参考文献2

共引文献18

同被引文献22

  • 1康振华,王为忠,陈冬利,王春艳,朱参胜,杜俊峰,金伯泉.抗人RANTES分子单克隆抗体的制备及特性鉴定[J].细胞与分子免疫学杂志,2005,21(3):322-324. 被引量:10
  • 2褚学者,姜述德,孙明波,周铁群,方捍华,杨建勇,张新文,潘玥,李卫东,廖国阳.抗脊髓灰质炎病毒Ⅱ型Sabin株D抗原单克隆抗体的研制[J].免疫学杂志,2006,22(4):387-389. 被引量:3
  • 3Centers for Disease Control and Prevention (CDC). Progress toward eradication of polio-worldwide, january 2011-March 2013 [J]. MMWR Morn Mortal Wkly Rep, 2013, 62(17): 335 -338.
  • 4Jenkins HE, Aylward RB, Gasasira A, et al. Implications of a circulating vaccine-derived poliovirus in Nigeria [J]. N Eng! J Med, 2010, 362(25) : 2360 -2369.
  • 5Centers for Disease Control and Prevention (CDC). Evaluating surveillance indicators supporting tbe Global Polio Eradication Initiative, 2011 - 2012 [J]. MMWR Morb Mortal Wkly Rep, 2013, 62 (14 ) : 270 -274.
  • 6Callaway E. Public health, polio's moving target [J]. Nature, 2013, 496 (7445) : 290 - 292.
  • 7Kazi A, Murtaza A, Khoja S, et al. Monitoring polio supplementary immunization activities using an automated short text messaging system in Karachi, Pakistan [J]. Bull World Health Organ, 2014, 92(3): 220 -225.
  • 8Levitt A, Diop OM, Tangermann RH, et al. Surveillance systems to track progress toward Global Polio Eradication-worldwide, 2012 -2013[J]. MMWR Morb Mortal Wkly Rep, 2014, 63(16): 356 - 361.
  • 9Saraswathy Subnunaniam TS, Apandi MA, Jahis R, et al. Viral aetiology of acute flaccid paralysis surveillance cases, before and after vaccine Policy change from oral polio vaccine to inactivated Polio vaccine [J/OL]. J Trop Med, 2014, 2014: 814908.
  • 10Parker EP, Kampmann B, Kang G, et al. Influence of enteric infections on response to oral poliovirus vaccine: A systematic review and meta-analyeiaj L]. J Infect Dis, 2014, 210(6): 853 -864.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部